TERT and cancer: The newly described gremlin and recurrent somatic mutations in melanoma and other cancers in the TERT promoter, which create de novo E-twenty six/ternary complex factors (Ets/TCF) binding sites,44, 45 provide an insight into the possible cause of tumor-specific increased TERT expression.